Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q2 2018 · 10-Q
Revenue$2.38M$2.38M+60.8% vs Q2 2017 Net Income-$9.41M-$9.41MN/M vs Q2 2017 EPS Diluted-$0.46-$0.46N/M vs Q2 2017 Operating Income-$9,670,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,079,000N/M Margins · derivedOperating margin-406.6%+47.7 pt vs Q2 2017
Net margin-395.9%+52.5 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 9, 2018 · 40 d after period end